Turkish Journal of Medical Sciences
Volume 41

Number 5

Article 6

1-1-2011

Subclinical hypoxia of infants with intrauterine growth retardation
determined by increased serum S100B protein levels
ÖZLEM KIRMEMİŞ
MUSTAFA MANSUR TATLI
CÜNEYT TAYMAN
CEMİLE KOCA
AHMET KARADAĞ

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KIRMEMİŞ, ÖZLEM; TATLI, MUSTAFA MANSUR; TAYMAN, CÜNEYT; KOCA, CEMİLE; KARADAĞ, AHMET;
URAS, NURDAN; DİLMEN, UĞUR; and KAFALI, HASAN (2011) "Subclinical hypoxia of infants with
intrauterine growth retardation determined by increased serum S100B protein levels," Turkish Journal of
Medical Sciences: Vol. 41: No. 5, Article 6. https://doi.org/10.3906/sag-1007-948
Available at: https://journals.tubitak.gov.tr/medical/vol41/iss5/6

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Subclinical hypoxia of infants with intrauterine growth retardation determined by
increased serum S100B protein levels
Authors
ÖZLEM KIRMEMİŞ, MUSTAFA MANSUR TATLI, CÜNEYT TAYMAN, CEMİLE KOCA, AHMET KARADAĞ,
NURDAN URAS, UĞUR DİLMEN, and HASAN KAFALI

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol41/iss5/6

Ö. KIRMEMİŞ, M. M. TATLI, C.TAYMAN, C. KOCA, A. KARADAĞ, N. URAS, U. DİLMEN, H. KAFALI
Turk J Med Sci
2011; 41 (5): 795-800
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
Original Article
doi:10.3906/sag-1007-948

Subclinical hypoxia of infants with intrauterine growth
retardation determined by increased serum S100B protein levels
Özlem KIRMEMİŞ1, Mustafa Mansur TATLI2, Cüneyt TAYMAN2, Cemile KOCA3, Ahmet KARADAĞ4,
Nurdan URAS5, Uğur DİLMEN5, Hasan KAFALI6

Aim: To test the hypothesis that serum S100B levels could be useful in detecting neurological damage in infants with
intrauterine growth retardation (IUGR).
Materials and methods: The study group consisted of infants with IUGR and the control group consisted of agematched healthy infants. S100B protein levels were measured after birth and compared between groups.
Results: For this study, 43 infants with IUGR and 25 infants as a control group were recruited. Gender, gestational age,
type of delivery, and maternal age of the groups were statistically insignificant, with the exception of the mean birth
weights (2120 ± 450 g in the IUGR group and 3096 ± 570 g in the control group (P < 0.001), respectively). S100B protein
levels of the IUGR infants (1.13 ± 0.54) were significantly higher than those of the control group (0.45 ± 0.13) (P <
0.001). IUGR infants treated with antenatal steroids showed lower S100B levels than IUGR infants that did not receive
antenatal steroid treatments (P < 0.05). The study group infants were divided into 2 groups, for growth retardation (GR)
that was asymmetric (n = 15) and symmetric (n = 28). The asymmetric and symmetric GR infants’ S100B levels were
1.14 ± 0.47 pg/mL and 1.21 ± 0.34 pg/mL, respectively, and no significant differences were found between the 2 groups
in terms of S100B levels (P = 0.32).
Conclusion: The results of this study favor the opinion that there is an existing intrauterine hypoxia causing hypoxic
brain tissue damage in IUGR infants, even when followed up with modern obstetrical screening protocols. Measurements
of S100B may be useful in the prediction of outcome in these infants.
Key words: S100B, IUGR, intrauterine growth retardation, intrauterine hypoxia

İntrauterin büyüme gerelikli infantların subklinik hipoksilerinin artmış serum
S100B protein seviyeleri ile saptanması
Amaç: Bu prospektif çalışmada intrauterin gelişme geriliği (IUGR) olan infantlarda nörolojik hasarı tespit etmede
S100B seviyelerinin faydalı olduğu hipotezi test edildi.
Yöntem ve gereç: Çalışma grubu İUGR infantlardan ve kontrol grubu benzer yaştaki sağlıklı infantlardan oluşmaktaydı.
S100B protein seviyeleri doğum sonrası ölçüldü ve 2 grup karşılaştırıldı.
Bulgular: Kırk üç IUGR ve kontrol grubunda 25 infant çalışmaya alındı. Cinsiyet, gestasyonel yaş, doğum şekli ve
grupların maternal yaşı arasında ortalama doğum ağırlığı (sırasıyla IUGR grubunda 2120 ± 450 g kontrol grubunda
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3096 ± 570 g (P < 0,001)) haricinde istatistiksel farklılık yoktu. S100B protein seviyleri IUGR infantlarda (1,13 ± 0,54)
kontrol grubundan (0,45 ± 0,13) anlamlı derecede daha yüksek bulundu (P < 0,001). S100B seviyelerinin antenatal
steroid tedavisi alan IUGR infantlarda antenatal steroit tedavisi almayan İUGR infantlara göre daha düşük düzeyde
olduğu gösterildi (P < 0,05). Çalışma grubundaki infantlar asimetrik (n = 15) ve simetrik (n = 28) gelişme geriliği olmak
üzere 2 gruba ayrıldılar. Asimetrik ve simetrik gelişme geriliği olan infantların S100B seviyeleri sırasıyla 1,14 ± 0,47
pg/mL ve 1,21 ± 0,34 pg/mL idi. İki grup arasında S100B seviyesi bakımından anlamlı farklılık bulunmadı (P = 0,32).
Sonuç: Bu çalışmanın sonuçları modern obstetrik metodlarla takip edilse de, İUGR infantlarda hipoksik beyin hasarına
neden olan intrauterin hipoksi varlığı düşüncesini desteklemektedir. Bu proteinin ölçülmesi bu infantların akibetlerini
tahmin etmede yaralı olabilir.
Anahtar sözcükler: S100B, IUGR, intrauterin gelişme geriliği, intrauterin hipoksi

Introduction
Placental insufficiency, with a consequent
reduction in fetal nutritive and oxygen supply, is one
of the most important causes of intrauterine growth
restriction (IUGR) and fetal hypoxia, which is one of
the main causes of perinatal mortality and morbidity
(1,2). Episodes of acute and chronic fetal hypoxia
can result in brain lesions, which may leave longterm neurological sequelae such as auditory and
visual impairment, mental retardation, and seizure
disorders. Moreover, minimal brain alterations,
such as a reduction in learning capabilities, dyslexia,
and attention-deficit/hyperactivity disorder, could
originate from the prenatal and/or perinatal exposure
to hypoxia (2-4). Nowadays, the management
of IUGR includes the combination of serial
morphological ultrasound examinations to assess
fetal growth and amniotic fluid quantity, combined
with functional testing such as a biophysical profile,
fetal heart rate testing, and Doppler examinations
of fetal hemodynamics (5). Unfortunately, even if
hypoxia is detected, none of the presently available
tests can define the amount of hypoxia that the
fetus can endure without developing hypoxic brain
lesions or the length of duration. Only the answers
to these questions would enable the definition of the
optimal timing of delivery in the case of chronic fetal
hypoxia and prevention of perinatal brain damage.
Although in this situation the delay of the delivery
might cause the prolongation of fetal exposure to
hypoxia, which could affect brain development and
cause brain damage, early delivery carries the risk
of prematurity and associated risk of neurological
disorders. Additionally, IUGR infants may show
hyperreflexia, hyporeflexia, jitteriness, and/or
796

hypertonicity in their early life. In most situations,
neurological examinations of IUGR infants are
uneventful and there is no evidence for the prediction
of long-term neurological disorders in these babies
(3,4,6). Therefore, the ability to monitor high-risk
fetuses in the perinatal period by use of biochemical
indexes could be particularly useful in detecting
cases at risk of adverse neurological outcomes, and
in determining the timing of insults that damage
the central nervous system as early as possible with
respect to future measures of prevention.
S100B is an acidic calcium-binding protein
that is released by brain tissue and is known to
be highly specific to the nervous system (7). It is
thought to play a dual role in the regulation of cell
function, being beneficial to cells at low doses but
detrimental at high doses. The protein appears to be
most abundant in glial cells, although its presence
in neuronal subpopulations has also been reported.
These findings have answered the question about the
putative role of S100B in brain injury (8). Therefore,
increased S100B concentrations in biological fluids
(e.g. cerebrospinal fluid, blood, urine, and amniotic
fluid) of adults, infants, and fetuses after cell injury in
the nervous system have supported the use of S100B
as a biochemical marker of brain damage (7). It was
found that this protein is increased in demyelinating
brain diseases, phenylketonuria, and especially
in hypoxic-ischemic brain damage (HI) (7,9).
S100B in the blood was measured, hypothesizing
that during active brain injury, the protein could
be released from the damaged tissue and part of
it could spread into the systemic circulation, also
as a result of the hemodynamic rearrangement of
the blood-brain barrier. In this regard, increased
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concentrations of S100B were detected 48-72 h
before any clinical, laboratory, or ultrasonographic
signs of intraventricular hemorrhage in preterm
newborns and of hypoxic ischemic encephalopathy
(HIE) in full-term newborns (8). Currently, there are
few studies about S100B in the serum of infants with
IUGR that are under risk of perinatal brain damage
(10-12).
In the present study, we aimed to investigate
the serum S100B levels in infants with IUGR
to provide early prediction of possible negative
neurodevelopmental outcomes, for both early and
later life in this particular population.
Materials and methods
The study was performed at 2 different tertiary
referral centers for obstetrics and neonatal intensive
care units from February to July of 2007. We studied
43 women with singleton pregnancies complicated
by IUGR, between the 30th and 42nd weeks of
gestation. Informed consent was obtained from
both hospitals’ ethics committees and the parents.
Gestational age was determined by clinical data
and by a first trimester ultrasound scan. IUGR was
defined by the presence of ultrasonographic signs
(biparietal diameter below the 10th percentile and
abdominal circumference below the 5th percentile)
according to the nomograms of Campbell and
Thoms (7,13). A drop in the percentile of fetal sizes
was recorded between the first scan after referral and
the final scan before delivery. Fetal growth restriction
was confirmed by a birth weight below the 10th
percentile in all of the fetuses. The ponderal index
was calculated for each of the GR infants. Afterwards,
infants were divided into 2 groups related to the
ponderal index: asymmetric GR infants (<50% of
ponderal index) and symmetric GR infants (>50%
of ponderal index) (14). The control group consisted
of 25 normal fetuses, matched for gestational age at
sampling (range: 30-42 weeks of gestation) and birth
weights between the 10th and 90th percentiles.
All women, in both the study and the control
groups, gave birth either vaginally or by elective
cesarean section, based on obstetric indications. At
delivery, the umbilical cord was clamped before any
signs of breathing were seen and blood was drawn

from the umbilical vein for the standard assessments
(blood cell count, alanine aminotransferase, aspartate
aminotransferase, blood urea, creatinine, glucose,
electrolytes, interleukin-6, and C-reactive protein).
Infants that fulfilled all of the following criteria
were admitted to the study: no maternal illness, no
signs of fetal distress, a pH greater than 7.2 in cord
blood or venous blood, and Apgar scores above 7
at 1 and 5 min. Exclusion criteria were multiple
pregnancies and maternal alcohol or cocaine
addiction, infants with any malformation, cardiac
or renal diseases, hemolytic disease, or intrauterine
infections.
Peripheral venous blood samples for S100B
measurement were obtained from a peripheral vein
12 h after birth and centrifuged immediately at 5000
g for 10 min, and the sera were stored at –80 °C until
concentration analyses were performed. All serum
samples for S100B were of good quality without
hemolysis. The S100B serum levels were determined
by fully automatic electrochemoluminometric
immunoassay (Elecsys S100®; Roche Diagnostics,
Penzberg, Germany) with a measurement range of
0.005-39 ng/L.
A neurological examination was performed at
the same time as the blood sampling and during
hospital discharge. Neonatal neurological conditions
were classified as normal or abnormal. An infant
was considered to be abnormal when one or more of
the following neurological syndromes were present:
hypo- or hyperkinesias, hyper- or hypotonicity,
dystonia, hemisyndrome, apathy syndrome, or
hyperexcitability syndrome.
Statistical analysis
For evaluation of the distribution of S100B
measurement results, histogram and KolmogorovSmirnov tests were applied. Student’s t-test was used
for statistical evaluation of continuous variables.
Relationships between S100B protein levels and birth
weight, birth length, maternal age, and gestational
age were evaluated with Pearson’s correlation
analysis. The gender of the infants, type of birth,
and type of anesthesia were compared to each other
using the chi-square test. Data were analyzed with
SPSS version 13.0 (SPSS Inc., Chicago, USA) with
significance defined as P < 0.05.
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Results
The findings of the study are summarized in
the Table. The study group consisted of 43 infants
and the control group of 25 infants. No significant
differences between the 2 groups were found in terms
of gender, gestational age at delivery, type of delivery,
antenatal glucocorticoid treatment, and maternal
age, with the exception of birth weight. The birth
weights of the 2 groups were 2120 ± 450 g in the
IUGR group and 3096 ± 570 g in the control group
(P < 0.001), respectively. There were no significant
differences in the laboratory parameters (red blood
cell count, alanine aminotransferase, aspartate
aminotransferase, blood urea, creatinine, glucose,
electrolytes (sodium, potassium, and calcium),
interleukin-6, and C-reactive protein) between the
IUGR and control groups upon admission to the
neonatal intensive care unit (P > 0.005). The study
and the control group were found to be similar
with respect to neurological examinations. In both
groups, none of the infants showed neurological
abnormalities at the time of discharge from the
hospital, and no overt neurological syndromes were
observed during recovery. Isolated and transient
symptoms,
including
hypertonia/hypotonia,

dystonia, and hyperexcitability, were shown in 15
of the IUGR infants and in 11 of the control infants.
Mean fetal S100B levels in the IUGR group (1.13 ±
0.54 pg/mL) were significantly higher (P < 0.001)
than those in the control group (0.4 ± 0.13 pg/
mL). There was a weak and low correlation between
gestational age and S100B protein levels (r = 0.24, P
= 0.12) and a weak and low correlation between birth
weight and S100B protein levels (r = –0.2, P = 0.006).
When the IUGR fetuses were grouped according to
antenatal steroid treatment, status of neurological
examination, type of delivery, and type of anesthesia
during delivery, those groups were found to be similar
with respect to these parameters, except for the
presence of antenatal steroid treatment. IUGR infants
treated with antenatal steroids showed lower S100B
levels than those without antenatal steroid treatment
(P < 0.05). The study group infants were divided into
2 groups: asymmetric GR and symmetric GR. The
asymmetric GR group consisted of 15 neonates, and
the symmetric SGA group consisted of 28 neonates.
The asymmetric and symmetric GR infants’ S100B
levels were 1.14 ± 0.47 pg/mL and 1.21 ± 0.34 pg/
mL, respectively, and no significant differences were
found between the 2 groups in terms of S100B levels
(P = 0.32).

Table. Characteristics of the study population and comparison of intrauterine growth retardation
(IUGR) and control groups.
IUGR
(n = 43)

CONTROL
(n = 25)

P

Maternal age (mean ± SD, years)

28.4 ± 4.0

28.8 ± 4.5

0.7

Gestational age at delivery (mean ± SD, weeks)

37.7 ± 2.8

38.0 ± 2.5

0.6

22/21

14/11

0.7

2120 ± 450

3096 ± 570

<0.001

Maternal glucocorticoid treatment (N/%)

11/25

5/20

0.5

Type of delivery (cesarean/vaginal)

26/17

13/12

0.5

Type of anesthesia during delivery (general/regional)

23/20

15/10

0.6

Neurological examination (normal/abnormal)

28/15

14/11

0.9

1.13 ± 0.54

0.45 ± 0.13

<0.001

Gender (male/female)
Birth weight (mean ± SD, g)

S100B protein (pg/mL)
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Discussion
The present study showed that S100B levels
increased in infants with IUGR at birth, and
asymmetric and symmetric GR infants had similar
S100B levels. Additionally, IUGR newborns with
an abnormal neurological outcome had similar
S100B levels as infants with IUGR and an uneventful
neurological follow-up. The present study was not
the first to report the increased level of S100B protein
in IUGR infants. Previous human studies showed
that the continuous release of the protein from
damaged nervous tissue was the main cause of the
high level of S100B in blood obtained from preterm
and term infants with IUGR, due to chronic hypoxia
(7,10,12,15). Additionally, animal studies have shown
that intrauterine hypoxia is associated with persistent
elevations of S100B protein in plasma, which supports
S100B as a useful early marker of fetal hypoxia (16). It
was also shown that S100B protein levels in maternal
and umbilical blood were increased in IUGR fetuses
and represented cerebral cell damage in the perinatal
period (17).
Although S100B is a protein mainly concentrated
in the central nervous system, it was shown that
pathological conditions that develop during
pregnancy affect the S100B level in the placenta,
umbilical cord tissue, fetal membranes, amniotic
fluid, and the fetal cord blood (17). Therefore,
biochemical markers in the umbilical vein blood
also reflect placental function. The half-life of this
protein is approximately 1 h (4). Therefore, placental
production might affect the serum levels of the
protein in the early hours of life, but is obviously not
responsible for the high levels found at later points
in time. It is suggested that elevated S100B levels 12
h after birth are a useful tool for the early detection
of neurological events in infants (18). In this regard,
in this study, blood samples were obtained from
a peripheral vein 12 h after birth to measure the
accurate levels of S100B and to exclude placental
contributions.
These findings, and the evidence that blood levels
of S100B were particularly high in IUGR newborns
with and without abnormal short-term neurological
outcomes, together suggest that the level of S100B
may reflect the extent of brain damage after
intrauterine hypoxic insult. The lack of difference

in S100B levels between IUGR infants with normal
and abnormal short-term neurological outcomes
supports the concept that the neurological symptoms
observed in the first few months after birth in
preterm infants who will develop cerebral palsy
are neither sensitive nor specific enough to ensure
reliable prognoses. Irritability, abnormal finger
posture, spontaneous Babinski reflex, weakness of
the lower limbs, transient abnormality of tone, and a
delay in achieving motor milestones are some of the
neurological signs that have been described in these
high-risk preterm infants (6). All of these symptoms
may be encountered before the onset of cerebral
palsy or during “transient dystonia,” dissociated
motor development, and other transient neurological
disturbances, which disappear during the first or
second year of life. Moreover, no correlations have
been found among any of these symptoms and the
severity of future motor impairment (6). Therefore,
a traditional neurological examination fails to
predict the development and severity of long-term
neurological abnormalities.
Antenatal glucocorticoids are widely used in
premature infants, where they reduce neonatal
morbidity and mortality. IUGR fetuses are at risk
of preterm delivery and thus are likely to receive
antenatal glucocorticoids to promote lung maturation.
Because glucocorticoids alter vascular tone, it was
questioned whether such treatment may induce
fetal cardiovascular alterations in IUGR infants;
some authors claimed that the fetal cardiovascular
response to maternal betamethasone administration
in IUGR fetuses is significantly different than that
seen in healthy fetuses (19). The IUGR fetus displays
rebound cerebral perfusion that is not seen in the
healthy fetus, which is associated with increased
oxidative stress and apoptosis in the fetal brain.
Therefore, maternally administered glucocorticoids
may have deleterious effects on the brain of IUGR
fetuses. In light of this fact, it is logical to expect a
higher level of S100B in steroid-administered groups,
but our results contradicted this hypothesis rather
than supporting it.
To date, there have been no human studies that
evaluated the relationship between antenatal steroid
administration and S100B protein blood level in
IUGR infants. However, there was one animal study
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that investigated the effects of a single course of
antenatal betamethasone on S100B concentrations
in preterm rats, in which a clinically equivalent dose
and half of this dose was used (19). The authors
found that the hippocampal S100B content was
reduced by a clinically equivalent dose of 12 mg
twice, but not by half of this dose. Interestingly, the
effect of betamethasone on brain cell proliferation
also showed a dose-dependent pattern, as
investigated in the same hippocampal homogenates.
The authors speculated that lowering the dose of
antenatal steroids may be less detrimental for brain
maturation.

Conclusion
The results of this study and previous studies
warrant consideration and favor the opinion that
there is an existing intrauterine hypoxia causing
hypoxic brain tissue damage in IUGR infants, even
when followed up with modern obstetrical screening
protocols. The major goals of modern obstetric
screening procedures are the identification of growthrestricted fetuses among the small-for-gestationalage fetuses. Early detection of fetal hypoxia in highrisk pregnancies and timely termination of high-risk
pregnancies will prevent the development of hypoxic
brain injury.
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